EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

The Role of PD-1 and CTLA-4 Blockade in Immunotherapy: Mechanisms of Action and Therapeutic Efficacy in Overcoming Lung Cancer Immune Evasion

Mojeeb Abdo Abdullah Qasem, Theresia Indah Budhy, Desak Gede Agung Suprabawati, Waode Fifin Ervina, Faheem Q. AL-Mojahid

Health Dynamics · 13.07.2026 · 3 (7) · 267-283

DOI: 10.33846/hd30702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Dynamics, online erschienen am 13.07.2026. Verfasst von Mojeeb Abdo Abdullah Qasem und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases and small cell lung cancer (SCLC) representing a highly aggressive neuroendocrine subtype with a poor prognosis. Tumor cells evade immune surveillance by co-opting immune checkpoint pathways, principally programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This review evaluates the mechanisms and therapeutic potential of PD-1 and CTLA-4 blockade in overcoming immune evasion in lung cancer. A structured narrative literature review synthesized evidence from preclinical studies, landmark clinical trials including KEYNOTE-001 and IMpower133, biomarker investigations, and mechanistic research on PD-1/PD-L1 and CTLA-4 pathways in NSCLC and SCLC. PD-1 suppresses effector T-cell activity and enhances regulatory T-cell function within the tumor microenvironment, while CTLA-4 attenuates T-cell priming through competitive B7 ligand binding. Immune escape is further mediated by HLA class I downregulation, impaired antigen presentation, immunosuppressive cytokine signaling, and tumor-infiltrating regulatory T cells. ICI monotherapy significantly improves overall survival in NSCLC with PD-L1 expression ≥50% compared with platinum-based chemotherapy. First-line atezolizumab plus chemotherapy extended median overall survival to 12.3 months, compared with 10.3 months in extensive-stage SCLC. Dual PD-1/CTLA-4 blockade produces synergistic antitumor responses; however, 70–85% of NSCLC patients develop primary or acquired resistance. PD-1 and CTLA-4 blockade has transformed the therapeutic landscape of lung cancer, yet resistance mechanisms, immune-related adverse events, and the absence of validated predictive biomarkers remain critical challenges. Future research must prioritize combination strategies, novel checkpoint targets, and multifactorial biomarker panels to broaden clinical benefit.

Zitieren

APA

Qasem, M. A. A., Budhy, T. I., Suprabawati, D. G. A., Ervina, W. F., & AL-Mojahid, F. Q. (2026). The Role of PD-1 and CTLA-4 Blockade in Immunotherapy: Mechanisms of Action and Therapeutic Efficacy in Overcoming Lung Cancer Immune Evasion. Health Dynamics, 3(7), 267-283. https://doi.org/10.33846/hd30702

Vancouver

Qasem MAA, Budhy TI, Suprabawati DGA, Ervina WF, AL-Mojahid FQ. The Role of PD-1 and CTLA-4 Blockade in Immunotherapy: Mechanisms of Action and Therapeutic Efficacy in Overcoming Lung Cancer Immune Evasion. Health Dynamics. 2026;3(7):267-283. doi:10.33846/hd30702

BibTeX
@article{Qasem2026,
  author = {Qasem, Mojeeb Abdo Abdullah and Budhy, Theresia Indah and Suprabawati, Desak Gede Agung and Ervina, Waode Fifin and AL-Mojahid, Faheem Q.},
  title = {The Role of PD-1 and CTLA-4 Blockade in Immunotherapy: Mechanisms of Action and Therapeutic Efficacy in Overcoming Lung Cancer Immune Evasion},
  journal = {Health Dynamics},
  year = {2026},
  volume = {3},
  number = {7},
  pages = {267--283},
  doi = {10.33846/hd30702}
}
Kostenlos starten →